Biostructural, biochemical and biophysical studies of mutant IDH1
We report bio-structural, bio-chemical and bio-physical evidence demonstrating how small molecules can bind to both wild-type and mutant IDH1, but only inhibit the enzymatic activity of the mutant isoform. Enabled through x-ray crystallography, we characterized a series of small molecule inhibitors that bound to mutant IDH1 differently than the marketed inhibitor Ivosidenib, for which we have determined the x-ray crystal structure. Across the industry several mutant IDH1 inhibitor chemotypes bind to this allosteric IDH1 pocket and selectively inhibit the mutant enzyme. Detailed characterization by a variety of biophysical techniques and NMR studies led us to propose how compounds binding in the allosteric IDH1 R132H pocket inhibit the production of 2-Hydroxy glutarate.
Authors
- Michael Hon‐Wah Lam (ORCID: https://orcid.org/0000-0003-1213-3874)
- Christian Fischer (ORCID: https://orcid.org/0000-0002-5023-1080)
- S.M. Soisson (ORCID: https://orcid.org/0000-0002-5089-3885)
- Mark A. McCoy (ORCID: https://orcid.org/0000-0003-3994-6605)
- F Richard Miller
- Jun Lü (ORCID: https://orcid.org/0009-0000-6292-2252)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Publication Details
- Journal
- Nature Communications
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1038/s41467-024-51692-0
- Citations
- 3
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.86